A detailed history of Federated Hermes, Inc. transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 995,000 shares of MORF stock, worth $33.9 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
995,000
Previous 1,000,000 0.5%
Holding current value
$33.9 Million
Previous $28.9 Million 21.27%
% of portfolio
0.08%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$26.64 - $40.31 $133,200 - $201,550
-5,000 Reduced 0.5%
995,000 $35 Million
Q4 2023

Jan 31, 2024

BUY
$19.95 - $31.0 $2.31 Million - $3.6 Million
115,975 Added 13.12%
1,000,000 $28.9 Million
Q3 2023

Nov 13, 2023

BUY
$21.33 - $59.42 $275,157 - $766,518
12,900 Added 1.48%
884,025 $20.3 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $8.25 Million - $14.9 Million
240,425 Added 38.12%
871,125 $49.9 Million
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $12,070 - $15,185
500 Added 0.08%
630,700 $16.9 Million
Q1 2022

May 13, 2022

BUY
$36.25 - $52.02 $11.6 Million - $16.6 Million
318,839 Added 102.4%
630,200 $25.3 Million
Q4 2021

Feb 14, 2022

SELL
$43.27 - $65.72 $503,489 - $764,717
-11,636 Reduced 3.6%
311,361 $14.8 Million
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $42,030 - $52,920
784 Added 0.24%
322,997 $18.3 Million
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $1 Million - $1.44 Million
22,170 Added 7.39%
322,213 $18.5 Million
Q1 2021

May 13, 2021

BUY
$29.77 - $84.85 $8.92 Million - $25.4 Million
299,766 Added 108218.77%
300,043 $19 Million
Q4 2020

Feb 12, 2021

BUY
$25.66 - $34.55 $3,874 - $5,217
151 Added 119.84%
277 $9,000
Q3 2020

Nov 12, 2020

BUY
$22.51 - $30.11 $2,836 - $3,793
126 New
126 $3,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.